Stem Cells Work in Heart Failure Trial
{{#rendered}} {{/rendered}}
Stem cell therapy from Australia's Mesoblast Ltd was well tolerated and showed real promise in treating heart failure patients, according to data from a small mid-stage clinical trial presented on Monday.
The therapy known as revascor after one year reduced by 78 percent the rate of major adverse events -- heart attacks, cardiac death and need for artery clearing procedures -- compared with patients who received current standard of care in the 60-patient trial.
The finding, which was presented at the American Heart Association scientific meeting in Orlando, was deemed statistically significant.
{{#rendered}} {{/rendered}}
Safety was the primary goal of the study and there were no cases of adverse events attributed to the Mesoblast stem cells, researchers said.
Load more..